Skip to content

The effect of omega3 on hot flash

The evaluation of omega3 effect versus placebo on hot flash in peri-menopausal women

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201102165737N1
Enrollment
60
Registered
2011-04-06
Start date
2009-05-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hot flash. General symptoms and signs

Interventions

Intervention 1: Intervention: omega3, Capsule 1000mg, oral, daily,for 3 months. Intervention 2: Control: placebo, Capsule, oral, daily, for 3 months.
Treatment - Drugs
Intervention: omega3, Capsule 1000mg, oral, daily,for 3 months
Control: placebo, Capsule, oral, daily, for 3 months

Sponsors

Tehran University of Medical Sciences and Health Services
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
45 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: women aged 45 to55 years, BMI=20-30, FSH>20, Having 2 hot flash attack per day Exclusion criteria: using clonidin, anti depressant agents, tamoxifen, raloxifen, antibiotics, anti acids, soya, vit E, or anti coagulants, any hormone therapy in the last 6 month, fish allergy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Rate of hot flash. Timepoint: before intervention/after each month of intervention/3,6month after intervention ended. Method of measurement: counting number of hot flash attack.;Severity of hot flash. Timepoint: before intervention/after each month of intervention/3,6 month after intervention ended. Method of measurement: menopause rating scale(MRS).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzadeh Rezaee

Tehran University of Medical sciences and Health Services

www.tums.ir+98 21 8860 2202

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026